Analyst Price Target is $14.50
▲ +61.83% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for InfuSystem in the last 3 months. The average price target is $14.50, with a high forecast of $15.00 and a low forecast of $14.00. The average price target represents a 61.83% upside from the last price of $8.96.
Current Consensus is
Buy
The current consensus among 5 contributing investment analysts is to buy stock in InfuSystem. This rating has held steady since October 2025, when it changed from a Strong Buy consensus rating.
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Read More
